That ressource is reserved for health professionals

This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.

I am a healthcare professional



Close menu



Risankizumab - Labelled (Arg,Lys) 13C15N


Quantification of Risankizumab

Specific labelling

Arginine: 13C6,15N4>99%

Lysine: 13C6,15N2, >99%


Risankizumab (Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Use in treatment of moderate to severe plaque psoriasis, moderate to severe Crohn's disease, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an inadequate response to conventional therapies.

This product is for research use only and is not intended for diagnostic or therapeutic use.